
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Holdings Ltd has demonstrated significant potential with its candidate rademikibart, which exhibited one of the largest reported improvements in FEV1 for any biologic during its Phase 2 asthma study, indicating its effectiveness in both acute and chronic treatment scenarios. The anticipated completion of IV dosing strategies and the expected clinical data by the end of 2025 suggest a promising commercial future, potentially increasing market uptake and revenue. Additionally, rademikibart's demonstrated rapid improvements in lung function, especially in eosinophilic subgroups, distinguishes it from existing chronic treatments, further reinforcing a positive outlook for the company's stock.
Bears say
Connect Biopharma Holdings Ltd faces significant challenges that contribute to a negative outlook for its stock. Increased competition within the biopharmaceutical market could restrict the company's market share and lead to sales outcomes below expectations. Additionally, potential patent disputes, difficulties in securing reimbursement, and the risk of unsuccessful clinical trial results may further undermine Connect's competitive position and revenue prospects.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares